PIERIS AG
Pieris Pharmaceuticals is a clinical-stage biotechnology company that develops drugs to fight cancer, severe asthma, anemia, and other medical conditions with unmet medical needs. The company applies its proprietary Anticalin® technology to the drug development processes. Pieris Pharmaceuticals was founded in 2001 and is based in Freising, Bayern.
PIERIS AG
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2001-01-01
Address:
Hallbergmoos, Bayern, Germany
Country:
Germany
Website Url:
http://www.pieris-ag.com
Total Employee:
101+
Status:
Active
Contact:
+49 8161 1411400
Total Funding:
18.25 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Sectigo SSL Sectigo Domain SSL StackPath
Similar Organizations
Anteros Pharmaceuticals
Anteros Pharmaceuticals is a biotechnology company that develops drugs for fibrotic and other inflammatory diseases.
Fovea Pharmaceuticals
Fovea Pharmaceuticals is a French biopharmaceutical company that discovers and develops drugs for the treatment of ocular diseases.
Modra Pharmaceuticals
Modra Pharmaceuticals is a clinical stage company that develops new treatment paradigms by enabling oral bioavailability.
Xenova
Xenova publicly quoted biotechnology company focused on the development of novel drugs to treat cancer and addiction.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Gilde IT Fund
Gilde IT Fund investment in Series B - Pieris AG
AAC Capital Partners
AAC Capital Partners investment in Series B - Pieris AG
BioM AG
BioM AG investment in Series B - Pieris AG
Forbion Capital Partners
Forbion Capital Partners investment in Series B - Pieris AG
BayTech Venture Capital
BayTech Venture Capital investment in Series B - Pieris AG
Global Life Science Ventures
Global Life Science Ventures investment in Series B - Pieris AG
BayTech Venture Capital
BayTech Venture Capital investment in Series A - Pieris AG
TransConnect
TransConnect investment in Series A - Pieris AG
Global Life Science Ventures
Global Life Science Ventures investment in Series A - Pieris AG
BioM Venture Capital
BioM Venture Capital investment in Series A - Pieris AG
More informations about "Pieris AG"
Pieris AG - Drug pipelines, Patents, Clinical trials - Synapse - Patsnap
Explore Pieris AG with its drug pipeline, therapeutic area, technology platform, 26 news, Disease Domain:Neoplasms, Technology Platform:Small molecule drug, Radiopharmaceuticals and diagnostic agent, Drug:PRS-110, 89Zr-PRS-110.See details»
Pieris AG - Crunchbase Company Profile & Funding
Pieris Pharmaceuticals is a clinical-stage biotechnology company that develops drugs to fight cancer, severe asthma, anemia, and other medical conditions with unmet medical needs. The company applies its proprietary Anticalin® technology to the drug development processes. Pieris Pharmaceuticals was founded in 2001 and is based in Freising, Bayern.See details»
Pieris AG - life-sciences-europe.com
Jan 1, 2001 Pieris AG is an independent, clinical-staged biotechnology company advancing its proprietary Anticalin® technology to create safer, more efficacious and more convenient protein therapeutics. Exclusive to Pieris, Anticalin-based drugs promise to address high-unmet medical needs and expand the therapeutic potential of current targeted approaches ...See details»
Pieris Pharmaceuticals GmbH - Bayern International
Pieris AG is an independent biotechnology company advancing its proprietary Anticalin® technology to create safer, more efficacious and more convenient protein therapeutics. Exclusive to Pieris, Anticalin-based drugs promise to address high-unmet medical needs and expand the therapeutic potential of current targeted approaches.See details»
Pieris AG - Funding, Financials, Valuation & Investors - Crunchbase
Series A - Pieris AG — TransConnect . No: Series A - Pieris AG — Global Life Science Ventures . Yes: Series A - Pieris AG . Hans Kupper: BioM Venture Capital . No: Series A - Pieris AG — Show More . Unlock even more features with Crunchbase Pro . Start Your Free Trial . Stay Connected. Crunchbase News ; Subscribe to the Crunchbase Daily ...See details»
Pieris AG: Drug pipelines, Patents, Clinical trials - Synapse
Explore Pieris AG with its drug pipeline, therapeutic area, technology platform, 16 news, and 3 literature, Drug:PRS-050.See details»
Pieris - VentureRadar
Pieris AG is a biopharmaceutical company engaged in the discovery and development of Anticalins® for the diagnosis and treatment of life-threatening human disorders. Exploiting extensive know-how in protein engineering as part of a broad intellectual property portfolio, the Company applies a balanced risk business model to the development of its Anticalin® …See details»
Pieris AG - Crunchbase
Pieris AG, Fovea Pharmaceuticals, Xenova, Anteros Pharmaceuticals, and Modra Pharmaceuticals are all part of the biopharmaceutical industry. Fovea Pharmaceuticals, Xenova, Anteros Pharmaceuticals, and Modra Pharmaceuticals focus on developing drugs for specific diseases, such as ocular diseases, cancer, addiction, fibrotic, and inflammatory diseases.See details»
Pieris AG - Innovations- und Gründerzentrum Biotechnologie IZB
Pieris AG ; Zeppelinstraße 3 ; 85399 Halbergmoos ; Deutschland ; Phone: +49 (0) 8161 / 141 14-00 ; Fax: ... Pieris is a biopharmaceutical company engaged in the discovery and development of Anticalins for the diagnosis and treatment of life-threatening human disorders. Exploiting extensive know-how in protein engineering as part of a broad ...See details»
Pieris Appoints a New CEO - Pieris Pharmaceuticals, Inc.
Pieris AG Stephen Yoder, CEO Phone +49 (0) 8161 1411 400 Email: [email protected]. About Pieris AG. Pieris is an independent biotechnology company devoted to Anticalins ®, a novel class of specific binding proteins that addresses an expansive range of therapeutic purposes and targets. Exploiting extensive know-how in protein engineering as ...See details»
PIERIS AG innovation strategy - GoodIP
PIERIS AG has a total of 121 patent applications. Its first patent ever was published in 1998. It filed its patents most often in WIPO (World Intellectual Property Organization), China and United States.Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are CHENGDU KANGHONG BIOLOG TECHNOLOGY CO LTD, INTERMUNE …See details»
Pieris Pharmaceuticals, Inc. Goes Public, Raises $12.2 Million
Dec 18, 2014 Pieris consummated the private placement following the completion of the share exchange transaction, pursuant to which Pieris AG became a wholly-owned subsidiary of the Company. In connection with the private placement, the Company issued to its co-exclusive placement agents and their designees warrants to acquire up to 487,629 shares of its common …See details»
Pieris Raises EUR 25 million in Series B Financing Round
Mar 27, 2008 FREISING-WEIHENSTEPHAN, Germany – Pieris AG, a bio-pharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, announced today the closing of a Series B financing round.. Led by new investor OrbiMed Advisors LLC, a major global fund dedicated to healthcare, together with Novo Nordisk A/S via …See details»
Pieris AG - Contacts, Employees, Board Members, Advisors & Alumni
Pieris Pharmaceuticals is a clinical-stage biotechnology company that develops drugs to fight cancer, severe asthma, anemia, and so on. Search Crunchbase Start Free TrialSee details»
Pieris AG HR Department | Pieris AG Human Resources
Pieris AG employs 121 employees. The Pieris AG management team includes Mary Fitzgerald (VP Respiratory Medicine), Trinh Lam (Analytical Scientist), and George Mensing (Clinical Project Manager). Get Contact Info for All Departments Pieris AG Org Chart Pieris AG Team GrowthSee details»
Pieris Pharmaceuticals, Inc.
With unique multispecifics, led by PRS-343 (wholly owned by Pieris) – Establish superior therapeutic window over mAbs – Improve on benefits of leading checkpoint antagonists and other therapies Develop best-in-class multi-checkpoint antagonists built on key backbone components (e.g. PD-1), led by PRS-332 (partnered with Servier)See details»
Pieris Pharmaceuticals - Gilde Healthcare
Dec 18, 2014 Pieris Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery and development of its proprietary Anticalin® class of biotherapeutics. The company has successfully developed a clinical-stage pipeline and closed commercial collaboration with firms like Daiichi Sankyo, Sanofi Pasteur and Allergan. Pieris …See details»
PRS-110 - Drug Targets, Indications, Patents - Synapse
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.See details»
Pieris AG - Updates, News, Events, Signals & Triggers - Crunchbase
Pieris Pharmaceuticals is a clinical-stage biotechnology company that develops drugs to fight cancer, severe asthma, anemia, and so on. Search Crunchbase Start Free TrialSee details»
Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 …
Skerra was a member of Pieris AG’s supervisory board when the parties entered into such agreement. The Company provided certain funding for TUM research efforts performed under the agreement. As a result of research efforts to date under the agreement, the Company holds a worldwide exclusive license under its license agreement with TUM to ...See details»